Compare · MODD vs RMD
MODD vs RMD
Side-by-side comparison of Modular Medical Inc. (MODD) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MODD and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $34.07B, about 1660.9x MODD ($20.5M).
- Over the past year, MODD is down 87.5% and RMD is down 11.9% - RMD leads by 75.6 points.
- MODD has been more active in the news (11 items in the past 4 weeks vs 9 for RMD).
- RMD has more recent analyst coverage (25 ratings vs 0 for MODD).
- Company
- Modular Medical Inc.
- ResMed Inc.
- Price
- -
- -
- Market cap
- $20.5M
- $34.07B
- 1M return
- -4.60%
- +4.60%
- 1Y return
- -87.49%
- -11.93%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 11
- 9
- Recent ratings
- 0
- 25
Modular Medical Inc.
Modular Medical, Inc., a development stage medical device company, focuses on the design, development, and commercialization of insulin pumps using technology to enhance pump adoption in the diabetes marketplace. The company is headquartered in San Diego, California.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest MODD
- Modular Medical Launches Digital Learning Tools to Support Adoption of Pivot Insulin Delivery System
- Modular Medical to Present at the Webull Emerging & Innovative Companies Webinar on October 14th
- Director Felsher Steven G was granted 25 shares, increasing direct ownership by 0.29% to 8,538 units (SEC Form 4)
- Director Desisto Duane M was granted 83 shares, increasing direct ownership by 0.89% to 9,412 units (SEC Form 4)
- Director Volkart Carmen B was granted 108 shares, increasing direct ownership by 12% to 1,036 units (SEC Form 4)
- SEC Form 4 filed by Director Goldberg Jeff D
- SEC Form 4 filed by Director Vos Ellen O'Connor
- SEC Form 4 filed by Director Sheibley Philip Brent
- SEC Form 4 filed by Director Frank Morgan C.
- SEC Form DEF 14A filed by Modular Medical Inc.
Latest RMD
- SEC Form 4 filed by ResMed Inc.
- SEC Form DEFA14A filed by ResMed Inc.
- SEC Form DEF 14A filed by ResMed Inc.
- Amendment: SEC Form 4 filed by Chairman and CEO Farrell Michael J.
- Chief Product Officer Leong Justin was granted 6,461 units of ResMed Common Stock, increasing direct ownership by 22% to 35,489 units (SEC Form 4)
- Global General Counsel Rider Michael J was granted 3,230 units of ResMed Common Stock, increasing direct ownership by 34% to 12,718 units (SEC Form 4)
- Chairman and CEO Farrell Michael J. was granted 13,547 units of ResMed Common Stock, increasing direct ownership by 3% to 479,803 units (SEC Form 4)
- Chief Financial Officer Bloomer Aaron was granted 9,072 units of ResMed Common Stock (SEC Form 4)
- Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026
- ResMed upgraded by RBC Capital Mkts with a new price target